^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    STAT3 mutation

    i
    Other names: STAT3, Signal Transducer And Activator Of Transcription 3, Acute-Phase Response Factor , APRF, Signal Transducer And Activator Of Transcription 3 (Acute-Phase Response Factor), DNA-Binding Protein APRF, ADMIO1, ADMIO, HIES
    Entrez ID:
    6774
    Related biomarkers:
    Expression
    Mutation
    Others
    1d
    STAT3/STAT5 Mutations Predict Shorter Overall Survival in Patients with Plasma Cell Myeloma. (PubMed, Eur J Haematol)
    STAT3/STAT5 mutations are early, dominant, and potentially pathogenic events in plasma cell myeloma. Their association with adverse clinical features and inferior survival supports their routine assessment and potential therapeutic targeting.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • STAT3 (Signal Transducer And Activator Of Transcription 3) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    |
    TP53 mutation • KRAS mutation • NRAS mutation • STAT3 mutation
    2d
    Immunological features of acquired pure red cell aplasia: Specific human leucocyte antigen alleles, signal transducer and activator of transcription 3 mutations and a unique T-cell receptor beta motif. (PubMed, Br J Haematol)
    Particularly among those with STAT3 mutations, the 'QGXG' motif in 15 AA sequences of TCRβ complementarity-determining regions 3 (CDR3) regions was specifically recognized. These findings suggest that a specific immunogenetic background defined by particular HLA alleles, the expansion of somewhat limited T-cell clones and STAT3-mutated T cells are involved in the pathogenesis of chronic acquired PRCA.
    Journal • IO biomarker
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • TRB (T Cell Receptor Beta Locus)
    |
    STAT3 mutation
    15d
    A critical role for STAT3 Thr714 phosphorylation in NPM-ALK-driven tumorigenesis. (PubMed, Sci Rep)
    In vivo, STAT3 knockdown suppressed tumor formation and hepatosplenomegaly in mice inoculated with Ba/F3 cells expressing NPM-ALK, and these phenotypes were rescued by wild-type STAT3, but not by the T714A mutant. These findings indicate that STAT3 phosphorylation at T714 is required for subsequent Y705 phosphorylation, nuclear translocation, and transcriptional activation specifically within the context of NPM-ALK-mediated signaling.
    Journal
    |
    CCND1 (Cyclin D1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PIM1 (Pim-1 Proto-Oncogene) • SOCS3 (Suppressor Of Cytokine Signaling 3)
    |
    ALK positive • ALK fusion • ALK wild-type • STAT3 mutation
    1m
    Constitutive STAT3 signaling, in comparison to STAT5, enhances CAR T cell efficacy and lowers systemic toxicity. (PubMed, Cancer Immunol Res)
    Coexpression of caSTAT3 and caSTAT5 markedly enhanced the long-term proliferative capacity of CAR T cells, even in the absence of antigen stimulation or cytokine supplementation. These findings elucidate the distinct impacts of STAT3 and STAT5 activation on CAR T cell behavior and suggest that selective activation of STAT3 at optimal levels may improve CAR T cell efficacy while minimizing off-tumor toxicities.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    |
    STAT3 mutation
    2ms
    T-LGLL: Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia (clinicaltrials.gov)
    P1/2, N=11, Active, not recruiting, Jonathan Brammer | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL15 (Interleukin 15)
    |
    STAT3 mutation
    |
    Onureg (azacitidine oral)
    2ms
    The value of T-cell receptor gene rearrangement in the auxiliary diagnosis of T-cell large granular lymphocytic leukemia (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    Patients with positive TCRγ gene rearrangement are more likely to develop STAT3 gene mutation. These characteristics may be helpful in the differential diagnosis of T-LGLL.
    Journal • IO biomarker
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • TRB (T Cell Receptor Beta Locus)
    |
    STAT3 mutation
    2ms
    Multi-omic Study of Cutaneous T-Cell Lymphoma Reveals Single Cell Clonal Evolution in Progression and Therapy Resistance. (PubMed, Blood)
    Our findings support an approach in which genomic analysis is widely utilized for improved disease monitoring, biomarker-informed clinical trial design, and genome-guided therapeutic decision making. Moreover, these molecular changes present new opportunities for therapeutic targeting in this challenging and incurable cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • CCR4 (C-C Motif Chemokine Receptor 4)
    |
    STAT3 mutation
    3ms
    Genetic mutations in lymphocytic variant of hypereosinophilic syndrome: study of five siblings. (PubMed, Front Med (Lausanne))
    Our findings support the role of immune dysregulation and genetic predisposition in L-HES and underscore the importance of broader genomic profiling in familial cases. Functional validation and long-term monitoring are essential for risk stratification and early detection of malignant transformation.
    Journal • IO biomarker
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • CD4 (CD4 Molecule) • IL5 (Interleukin 5)
    |
    STAT3 mutation
    3ms
    Mutational Spectrum of T-Cell Large Granular Lymphocytic Leukemia: Insights From the AACR Project GENIE Consortium. (PubMed, Cancer Genomics Proteomics)
    This study provides a comprehensive genomic profile of T-LGLL, identifying recurrent somatic mutations and commonly affected pathways. Notably, frequent alterations were observed in the FAS-FASL signaling pathway, underscoring its potential as a target for therapeutic development.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • DNMT3A (DNA methyltransferase 1) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • STAT3 (Signal Transducer And Activator Of Transcription 3) • FASLG (Fas ligand) • IKZF3 (IKAROS Family Zinc Finger 3) • TNFAIP3 (TNF Alpha Induced Protein 3) • EPHB1 (EPH Receptor B1) • SETD1B (SET Domain Containing 1B, Histone Lysine Methyltransferase) • STAT2 (Signal transducer and activator of transcription 2) • ALOX12B (Arachidonate 12-Lipoxygenase) • DDX3X (DEAD-Box Helicase 3 X-Linked)
    |
    TP53 mutation • STAT3 mutation
    4ms
    XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis. (PubMed, Cell Commun Signal)
    Selinexor and azacitidine offer a promising strategy to overcome therapeutic resistance and improve outcomes in TET2/RHOA-mutated PTCL, supporting further clinical evaluation.
    Journal • IO biomarker
    |
    TET2 (Tet Methylcytosine Dioxygenase 2) • JAK3 (Janus Kinase 3) • RHOA (Ras homolog family member A) • SOCS1 (Suppressor Of Cytokine Signaling 1)
    |
    TET2 mutation • STAT3 mutation
    |
    azacitidine • Xpovio (selinexor)
    4ms
    Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis. (PubMed, Br J Haematol)
    This work provides the first genomic characterisation of a diagnosed MDS cohort in China and establishes the first risk prediction model for MDS-to-AML transformation, alongside novel prognostic models for OS and PFS. These tools offer improved prognostic prediction and potential guidance for therapeutic strategies in Chinese patients with MDS.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • ETV6 (ETS Variant Transcription Factor 6) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • CSF3R (Colony Stimulating Factor 3 Receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • STAG2 (Stromal Antigen 2) • GATA2 (GATA Binding Protein 2) • CALR (Calreticulin)
    |
    TP53 mutation • SRSF2 mutation • STAT3 mutation
    4ms
    Diagnostic significance of gut Microbiome dysbiosis and biomarker expression in Egyptians with hepatocellular carcinoma. (PubMed, Sci Rep)
    A significant correlation between microbiome abundance and VEGF and MMP9 was observed. This study illustrated that gut microbiomes contribute to HCC and HCV-related cirrhosis pathogenesis, opening approaches for cancer management and prevention.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • MMP9 (Matrix metallopeptidase 9)
    |
    STAT3 mutation